The EBV-MS paradigm:beyond molecular mimicry toward new therapeutic strategiesOA
Epstein-Barr virus(EBV)is now recognized as the definitive environmental driver of multiple sclerosis(MS),shifting the conceptual landscape of this autoimmune disorder to an infection-triggered model.In this review,we systematically evaluate the multidimensional evidence linking EBV to MS.This evidence ranges from epidemiological associations and the identification of mimotopes to emerging therapeutic strategies.We also discuss the broader implications of infection-driven immune dysregulation for autoimmune research.This pathogenic link is underpinned by molecular mimicry,where immune responses against the viral protein EBNA1 cross-react with the central nervous system(CNS)protein GlialCAM.Beyond this initial insult,EBV reprograms B cells to survive and proliferate abnormally,creating a compartmentalized viral reservoir within the CNS that sustains chronic neuroinflammation.These mechanistic insights catalyze a transition from broad immunosuppression to precision therapies targeting the EBV-MS axis,including CNS-penetrant kinase inhibitors and EBV-specific CAR-T cells.By integrating etiological discovery with mechanism-based intervention,the EBV-MS paradigm serves as a blueprint for transforming idiopathic autoimmune diseases into mechanistically tractable conditions with actionable therapeutic targets.
Huating Xie;Weidong Huang;Weikun Li;Shiying Lai;Zhiqun lin;Rongqing Zhong;Wen Wang;Xu Lin;Zhaowei Xu
Key Laboratory of Gastrointestinal Cancer(Fujian Medical University),Ministry of Education,Fuzhou 350122,China Department of Medical Microbiology,Fujian Key Laboratory of Tumor Microbiology,School of Basic Medical Sciences,Fujian Medical University,Fuzhou 350122,China Department of Gastroenterology,90Oth Hospital of Joint Logistics Support Force,Fujian Medical University,Fuzhou 350025,ChinaKey Laboratory of Gastrointestinal Cancer(Fujian Medical University),Ministry of Education,Fuzhou 350122,China Department of Medical Microbiology,Fujian Key Laboratory of Tumor Microbiology,School of Basic Medical Sciences,Fujian Medical University,Fuzhou 350122,China Department of Gastroenterology,90Oth Hospital of Joint Logistics Support Force,Fujian Medical University,Fuzhou 350025,ChinaKey Laboratory of Gastrointestinal Cancer(Fujian Medical University),Ministry of Education,Fuzhou 350122,China Department of Medical Microbiology,Fujian Key Laboratory of Tumor Microbiology,School of Basic Medical Sciences,Fujian Medical University,Fuzhou 350122,ChinaKey Laboratory of Gastrointestinal Cancer(Fujian Medical University),Ministry of Education,Fuzhou 350122,China Department of Medical Microbiology,Fujian Key Laboratory of Tumor Microbiology,School of Basic Medical Sciences,Fujian Medical University,Fuzhou 350122,ChinaKey Laboratory of Gastrointestinal Cancer(Fujian Medical University),Ministry of Education,Fuzhou 350122,China Department of Medical Microbiology,Fujian Key Laboratory of Tumor Microbiology,School of Basic Medical Sciences,Fujian Medical University,Fuzhou 350122,ChinaKey Laboratory of Gastrointestinal Cancer(Fujian Medical University),Ministry of Education,Fuzhou 350122,China Department of Medical Microbiology,Fujian Key Laboratory of Tumor Microbiology,School of Basic Medical Sciences,Fujian Medical University,Fuzhou 350122,ChinaDepartment of Gastroenterology,90Oth Hospital of Joint Logistics Support Force,Fujian Medical University,Fuzhou 350025,ChinaKey Laboratory of Gastrointestinal Cancer(Fujian Medical University),Ministry of Education,Fuzhou 350122,China Department of Medical Microbiology,Fujian Key Laboratory of Tumor Microbiology,School of Basic Medical Sciences,Fujian Medical University,Fuzhou 350122,ChinaKey Laboratory of Gastrointestinal Cancer(Fujian Medical University),Ministry of Education,Fuzhou 350122,China Department of Medical Microbiology,Fujian Key Laboratory of Tumor Microbiology,School of Basic Medical Sciences,Fujian Medical University,Fuzhou 350122,China
医药卫生
Epstein-Barr virusmultiple sclerosisautoimmunitymolecular mimicry
《Acta Biochimica et Biophysica Sinica》 2026 (6)
P.1213-1222,10
supported by the grants from the Fujian Province Key Technological Innovation Research and Industrialization Project,China(No.2024XQ012)Fuzhou,Xiamen and Quanzhou National Independent Innovation Demonstration Zone Collaborative Innovation Platform Project,China(No.2024-P-004).
评论